Non-ST-Segment Elevation Myocardial Infarction

Detailed Overview

NSTEMI occurs when oxygen demand outstrips supply due to acute plaque rupture or erosion leading to thrombosis, but the vessel remains partially patent, or there is robust collateral circulation. Unlike unstable angina, NSTEMI involves actual myocardial death, evidenced by elevated cardiac biomarkers (Troponin). Management relies on risk stratification (e.g., TIMI or GRACE scores) to determine the timing of invasive angiography, accompanied by potent antiplatelet and antithrombotic therapies.

Epidemiology & Demographics

NSTEMI is the most common presentation of acute myocardial infarction, accounting for approximately 70% of all MI cases. Incidence increases with age and is more prevalent in patients with multiple comorbidities like diabetes and chronic kidney disease.

Etiological Mechanism

The primary etiology is the rupture or erosion of an atherosclerotic plaque in an epicardial coronary artery, leading to platelet aggregation and non-occlusive thrombus formation. Type 2 NSTEMI can occur from demand ischemia (e.g., severe anemia, sepsis, tachyarrhythmia) without acute plaque rupture.

Primary Causes

Coronary atherosclerosis with plaque rupture (Type 1 MI)

Supply/demand mismatch (Type 2 MI - e.g., tachycardia, anemia, hypotension)

Coronary artery spasm (Prinzmetal angina)

Coronary artery dissection

• Diabetes Mellitus: Accelerates atherosclerosis and increases the risk of atypical (silent) presentations.
• Hypertension: Causes endothelial dysfunction and promotes plaque formation.
• Smoking: Promotes a pro-thrombotic state and vasoconstriction.
• Hyperlipidemia: Elevated LDL cholesterol drives atheroma formation.

An atherosclerotic plaque containing a lipid-rich core and a thin fibrous cap ruptures, exposing subendothelial collagen and tissue factor. Platelets adhere, activate, and aggregate, triggering the coagulation cascade to form a fibrin mesh. In NSTEMI, the resulting thrombus is platelet-rich (white thrombus) and only partially occludes the vessel, or transiently occludes and spontaneously lyses. Blood flow is reduced but not completely cut off. The subendocardium, being the most distal tissue supplied and subjected to the highest wall tension, is the first to become ischemic and undergo necrosis, releasing intracellular proteins like Troponin into the bloodstream.

Characteristic Clinical Presentation

• Chest pain (Angina): Retrosternal pressure, heaviness, or squeezing, often radiating to the left arm, neck, or jaw. Occurs at rest or with minimal exertion and lasts > 20 minutes.
• Dyspnea: Shortness of breath, which may be an anginal equivalent in the elderly or diabetic.
• Diaphoresis: Cold sweats driven by sympathetic activation.
• Nausea/Vomiting: More common with inferior ischemia due to vagal stimulation.

Physical Examination Signs

• May be normal.
• S4 gallop (indicating a stiff, ischemic left ventricle).
• New mitral regurgitation murmur (papillary muscle ischemia).
• Tachycardia and hypertension (sympathetic drive), or hypotension (cardiogenic shock).

• Arrhythmias: Ventricular tachycardia or fibrillation.
• Heart Failure: If significant myocardial mass is lost, leading to HFrEF.
• Cardiogenic Shock: Severe pump failure causing multi-organ hypoperfusion.

Diagnostic Criteria & Guidelines

Diagnosis requires: 1) Clinical symptoms of ischemia, PLUS 2) A rise and/or fall of cardiac troponin values with at least one value above the 99th percentile upper reference limit, PLUS 3) Absence of ST-segment elevation on ECG (may have ST depression, T wave inversion, or be normal).

Differential Diagnosis

• Unstable Angina
• STEMI
• Pulmonary Embolism
• Aortic Dissection
• Acute Pericarditis

Laboratory Tests & Biomarkers

• High-Sensitivity Cardiac Troponin (hs-cTn): Elevated. Serial testing (e.g., at 0 and 2 hours) shows a dynamic rise or fall.
• Lipid Panel: Assessed to guide long-term statin therapy, often showing elevated LDL.
• Basic Metabolic Panel: To check renal function prior to contrast-enhanced angiography.

Imaging Modalities & Findings

• Electrocardiogram (ECG):
• Echocardiogram:
• Coronary Angiography:

• Ischemia
  Reversible cellular injury causing pain and ECG changes (ST depression/T wave inversion) but no necrosis yet (Unstable Angina).
• Infarction
  Irreversible necrosis evidenced by positive cardiac troponin.

Second-Line & Adjunctive Therapy

Risk stratification determines invasive strategy. High-risk patients (refractory pain, hemodynamic instability, GRACE score >140) undergo an early invasive strategy (Coronary Angiography within 24 hours). Low-risk patients may undergo an ischemia-guided strategy (non-invasive stress testing first).

Surgical & Procedural Management

Percutaneous Coronary Intervention (PCI) with drug-eluting stent placement is the primary revascularization method. Coronary Artery Bypass Grafting (CABG) is indicated for left main disease, severe three-vessel disease, or in diabetics with complex anatomy.

Recommended Lifestyle Changes

• Smoking cessation is mandatory.
• Cardiac rehabilitation program post-discharge.
• Heart-healthy diet (Mediterranean diet).

Patient Counseling & Advice

Emphasize strict adherence to Dual Antiplatelet Therapy (DAPT - Aspirin + P2Y12 inhibitor) for at least 12 months post-stent to prevent stent thrombosis. Educate on using sublingual nitroglycerin for future chest pain and calling emergency services if pain is not relieved after 1 dose.

Follow-Up & Monitoring Schedule

Cardiology clinic visit within 1-2 weeks of discharge. Regular lipid checks (Target LDL < 55 mg/dL). Repeat echocardiogram if LVEF was reduced.

Preventive Strategies

Aggressive management of hypertension, diabetes, and hyperlipidemia. Daily low-dose Aspirin (81 mg) and statin therapy.

In-hospital mortality is lower for NSTEMI than STEMI. However, NSTEMI patients often have more comorbidities and multi-vessel disease, making their long-term (1-3 year) mortality risk similar or even higher than STEMI patients.